QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
Log in

NASDAQ:UTHRUnited Therapeutics Stock Price, Forecast & News

$116.41
+4.94 (+4.43 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$113.06
Now: $116.41
$116.80
50-Day Range
$112.26
MA: $117.48
$124.18
52-Week Range
$75.58
Now: $116.41
$127.79
Volume332,712 shs
Average Volume595,890 shs
Market Capitalization$5.12 billion
P/E Ratio11.95
Dividend YieldN/A
Beta0.82
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing esuberaprost, RemoPro, Treprostinil Technosphere, Trevyent, ralinepag, and Aurora-GT to treat PAH; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. United Therapeutics Corporation has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin in the United States, the United Kingdom, Canada, France, Germany, Italy, and Japan; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop SM04646, a phase I development-stage Wnt pathway inhibitor for treating idiopathic pulmonary fibrosis. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Read More
United Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:UTHR
CUSIP91307C10
Phone301-608-9292

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.45 billion
Book Value$63.36 per share

Profitability

Net Income$-104,500,000.00

Miscellaneous

Employees860
Market Cap$5.12 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$116.41
+4.94 (+4.43 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive UTHR News and Ratings via Email

Sign-up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

How has United Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

United Therapeutics' stock was trading at $93.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, UTHR stock has increased by 23.9% and is now trading at $116.41.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of United Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for United Therapeutics
.

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for United Therapeutics
.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) announced its earnings results on Wednesday, July, 29th. The biotechnology company reported $2.41 earnings per share for the quarter, meeting the consensus estimate of $2.41. The biotechnology company had revenue of $362 million for the quarter, compared to the consensus estimate of $339.97 million. United Therapeutics had a net margin of 30.04% and a return on equity of 14.90%. The company's revenue was down 3.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.63 EPS.
View United Therapeutics' earnings history
.

What price target have analysts set for UTHR?

8 analysts have issued 1-year price objectives for United Therapeutics' shares. Their forecasts range from $80.00 to $244.00. On average, they anticipate United Therapeutics' stock price to reach $143.38 in the next year. This suggests a possible upside of 23.2% from the stock's current price.
View analysts' price targets for United Therapeutics
.

Has United Therapeutics been receiving favorable news coverage?

News headlines about UTHR stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. United Therapeutics earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days.
View the latest news about United Therapeutics
.

Are investors shorting United Therapeutics?

United Therapeutics saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 1,930,000 shares, a decrease of 17.2% from the June 30th total of 2,330,000 shares. Based on an average daily trading volume, of 594,400 shares, the days-to-cover ratio is presently 3.2 days. Approximately 4.6% of the shares of the company are sold short.
View United Therapeutics' Current Options Chain
.

Who are some of United Therapeutics' key competitors?

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Celgene (CELG), NVIDIA (NVDA), Applied Materials (AMAT), General Electric (GE), Johnson & Johnson (JNJ), Netflix (NFLX) and Exxon Mobil (XOM).

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the following people:
  • Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 64)
  • Mr. Michael I. Benkowitz, Pres & COO (Age 47)
  • Mr. James C. Edgemond, CFO & Treasurer (Age 51)
  • Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 55)
  • Kevin T. Gray, Sr. VP of Strategic Operations & Logistics

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include First Trust Advisors LP (1.42%), Robeco Institutional Asset Management B.V. (1.19%), Wedge Capital Management L L P NC (0.65%), Emerald Advisers LLC (0.45%), Emerald Mutual Fund Advisers Trust (0.39%) and State of Michigan Retirement System (0.36%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson.
View institutional ownership trends for United Therapeutics
.

Which major investors are selling United Therapeutics stock?

UTHR stock was sold by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Mackay Shields LLC, Cutler Group LP, GW Henssler & Associates Ltd., Cardinal Capital Management, First Quadrant L P CA, Dupont Capital Management Corp, and M&T Bank Corp. Company insiders that have sold United Therapeutics company stock in the last year include Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner, and Tommy G Thompson.
View insider buying and selling activity for United Therapeutics
.

Which major investors are buying United Therapeutics stock?

UTHR stock was purchased by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Wedge Capital Management L L P NC, State of Michigan Retirement System, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, UBS Group AG, Chartwell Investment Partners LLC, and Assenagon Asset Management S.A..
View insider buying and selling activity for United Therapeutics
.

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $116.41.

How big of a company is United Therapeutics?

United Therapeutics has a market capitalization of $5.12 billion and generates $1.45 billion in revenue each year. The biotechnology company earns $-104,500,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. United Therapeutics employs 860 workers across the globe.

What is United Therapeutics' official website?

The official website for United Therapeutics is www.unither.com.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.